Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023 07:05 ET
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Global Gastrointestinal Partnering Analysis Report 2023: Deal Trends, Players and Financials for Over 480 Deals Signed Since 2016 by the World's Leading Life Science Companies
May 31, 2023 03:13 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.Global...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
May 10, 2023 16:05 ET
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 10, 2023 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023 07:00 ET
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023 06:59 ET
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
April 18, 2023 16:01 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Organovo Announces FXR Program
March 21, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Stoma/Ostomy Care Global Market to Reach $5.1 Billion by 2030: Rising Incidence of Colorectal Cancer, Bladder Cancer and IBD and Drives the Need for Ostomy Care Products
March 02, 2023 11:43 ET
|
Research and Markets
Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Stoma/Ostomy...